Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs
Kathleen Ward(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Shruti H. Mehta(Johns Hopkins University), Robert K. Brooner(Johns Hopkins University), Stephanie Katz(Johns Hopkins University), Kayla Herne(Johns Hopkins University), Catherine G. Sutcliffe(Johns Hopkins University), Taryn Haselhuhn, Lilian Arteaga(Johns Hopkins University), Carl A. Latkin(Johns Hopkins University), Sherilyn Brinkley, Juhi Moon
Cited by 7
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694